Why these 4 ASX shares are sinking lower today

The S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) has had a day to forget and dropped notably lower in afternoon trade. At the time of writing the benchmark index is down a sizeable 0.75% to 6,126.3 points.

Four shares that have fallen more than most today are listed below. Here’s why they are sinking lower:

The Bionomics Ltd (ASX: BNO) share price has plunged 59% lower to 20.5 cents after revealing disappointing results from the phase 2 clinical trial of its BNC210 novel drug candidate in patients with Post Traumatic Stress Disorder (PTSD). The trial did not meet its primary endpoint of a decrease in PTSD symptoms as measured by Clinician-Administered PTSD Scale (CAPS-5) at 12 weeks. Management has suspended future work on the drug candidate. Its shares were down as much as 69% at one stage after this bitter blow.

The Blue Sky Alternative Investments Ltd (ASX: BLA) share price has tumbled almost 6% to $1.62. This decline means that the struggling asset manager’s shares have now given back almost all the gains made since announcing its deal with Oaktree Capital last week. While the news was a positive, I think it is still too soon to invest.

The Mesoblast limited (ASX: MSB) share price has dropped 11% lower to $2.08. Prior to today the allogeneic cellular medicines developer’s shares had been on a strong run and risen over 34% in the space of just one month. I suspect that some investors may be taking profit today. Which wouldn’t be a surprise given what happened to the Bionomics share price when its trial results fell short of expectations.

The Nick Scali Limited (ASX: NCK) share price has dropped 5% to $6.37. The majority of this decline can be attributed to the furniture retailer’s shares trading ex-dividend this morning for its fully franked 24 cents per share final dividend. Eligible shareholders can now look forward to receiving this on October 24.

Top 3 ASX Blue Chips To Buy In 2018

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool’s in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool’s Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies moves – we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…


The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!